Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 15/20 | 1.00 |
| ▸ | SRC | P12931 | 11/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.81 |
| ▸ | ABL1 | P00519 | 6/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.78 |
| ▸ | WEE1 | P30291 | 4/20 | 0.78 |
| ▸ | EGFR | P00533 | 4/20 | 0.78 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.78 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.78 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.78 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.78 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.78 |
| ▸ | JAK2 | O60674 | 1/20 | 0.78 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.78 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.78 |
| ▸ | PAK4 | O96013 | 1/20 | 0.78 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.78 |
| ▸ | LCK | P06239 | 1/20 | 0.78 |
| ▸ | FYN | P06241 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102543 | 0.92 | FGFR1 (0.86) | FGFR1SRCPDGFRBPDGFRAABL1 | |
| SCHEMBL5911585 | 0.91 | FGFR1 (0.83) | FGFR1SRCPDGFRBPDGFRAABL1 | |
| SCHEMBL1335649 | 0.90 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAABL1 | |
| Pd-0166285 SCHEMBL30250248 | 0.88 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAABL1 | |
| SCHEMBL29750113 | 0.88 | FGFR1 (0.78) | FGFR1SRCPDGFRBPDGFRAABL1 | |
| Pd-0166285 SCHEMBL133914 | 0.88 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAABL1 | |
| SCHEMBL4747103 | 0.88 | SRC (0.81) | FGFR1SRCPDGFRBPDGFRAABL1 | |
| SCHEMBL5764000 | 0.88 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAABL1 | |
| Pd-0166285 SCHEMBL15106017 | 0.87 | FGFR1 (0.98) | FGFR1SRCPDGFRBPDGFRAABL1 | |
| Pd-0166285 SCHEMBL30276696 | 0.87 | FGFR1 (0.98) | FGFR1SRCPDGFRBPDGFRAABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250116671-A1 | Kinase Activity In Tumors | INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-04-10 | — | — | US | claimed |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | claimed |
| EP-4460314-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-13 | — | — | EP | claimed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | claimed |
| US-20080220497-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS LLC | 2008-09-11 | — | — | US | claimed |
| EP-1907411-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | Deciphera Pharmaceuticals, LLC. (US) | 2008-04-09 | — | — | EP | claimed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | claimed |
| WO-2007008917-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | claimed |
| US-20060105445-A1 | Medium and method for enriching, purifying or depleting atp binding proteins from a pool of proteins | GPC BIOTECH AG (DE) | 2006-05-18 | — | — | US | claimed |
| EP-1527345-A2 | METHOD FOR ISOLATING ATP BINDING PROTEINS BY MEANS OF IMMOBILIZED PROTEIN INHIBITORS | Axxima Pharmaceuticals AG (DE) | 2005-05-04 | — | — | EP | claimed |
| WO-2004013633-A2 | METHOD FOR ISOLATING ATP BINDING PROTEINS BY MEANS OF IMMOBOLIZED PROTEIN INHIBITORS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-02-12 | — | — | WO | claimed |
| EP-3954436-B1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | ORIZURU THERAPEUTICS INC (JP) | 2026-01-07 | — | — | EP | disclosed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-1527345-A2 | METHOD FOR ISOLATING ATP BINDING PROTEINS BY MEANS OF IMMOBILIZED PROTEIN INHIBITORS | Axxima Pharmaceuticals AG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004013633-A3 | METHOD FOR ISOLATING ATP BINDING PROTEINS BY MEANS OF IMMOBOLIZED PROTEIN INHIBITORS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004013633-A2 | METHOD FOR ISOLATING ATP BINDING PROTEINS BY MEANS OF IMMOBOLIZED PROTEIN INHIBITORS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004013633-A2 | METHOD FOR ISOLATING ATP BINDING PROTEINS BY MEANS OF IMMOBOLIZED PROTEIN INHIBITORS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | FGFR1 3599/4885SRC 1334/4885PDGFRB 1552/4885 |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | DCX, SLC10A2, CHAT | FGFR1 2707/4885SRC 4575/4885PDGFRB 1721/4885 |
| US-20060105445-A1 | Medium and method for enriching, purifying or depleting atp binding proteins from a pool of proteins | ATP5MK, ATP5ME, ATP5MG | FGFR1 4232/4885SRC 3851/4885PDGFRB 1479/4885 |
| US-20080220497-A1 | Modulation of protein functionalities | C1QBP, SERPINA6, CD2BP2 | FGFR1 4698/4885SRC 2604/4885PDGFRB 3462/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | FGFR1 118/4885SRC 9/4885PDGFRB 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.